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Abstract. Due to the increase of the incidence of fungal infections 
in humans and the limitations of the available antimycotic drugs, 
among which the emergence of resistant strains, there is a need for 
the discovery of new antifungal agents. Plants, especially those 
used in Traditional Medicine, linked to an unmatched chemical 
diversity, either as pure compounds or as plant extracts, provide 
unlimited opportunities for the development of new antifungals. In 
recent years, compounds from different phytochemical groups have 
been described as having antifungal activity, including 
polyphenols, saponins, or peptides, among others, as well as 
essential oils and their constituents. After screening of 
ethnopharmacologically selected plants, mainly from Latin-
America, followed by bio-guided isolation, our group has 
described the antifungal activity of different types of plant 
constituents, such as sesquiterpenes, triterpenes, flavonoids, 
lignans, fatty acids and essential oils.  
  
Introduction 
 
 Fungal infections arise as an increasing health problem with a high 
economic cost. A recent study of the epidemiology of sepsis caused by               
fungi in USA showed that between 1979 and 2000 they increased by 207%.  
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The morbidity and mortality associated with these infections are substantial: 
deaths due to mycoses increased from 1557 in 1980 to 6534 in 1997, in                
the USA, and they were mainly associated with Candida, Aspergillus and 
Cryptococcus sp. infections [1-3]. 
 The most frequent fungal pathogens include the yeasts Candida sp., 
(mainly C. albicans and other species especially virulent, like C. glabrata) 
and Cryptococcus sp., filamentous fungi like Aspergillus sp., Fusarium sp. 
and Rhizopus sp., and the dermatophytes Trycophyton sp., Microsporum sp. 
and Epidermophyton sp. Particularly, Candida and Aspergillus represent          
70-90% and 10-20%, respectively, of all invasive fungal infections [4]. 
 A number of reasons have led to the significant augmentation of the 
incidence of fungal infections in humans in recent decades [1,4,5]: 
 
- The increase in the number of immunocompromised patients who 
frequently develop opportunistic superficial and systemic fungal 
infections.  
- The invasive medical procedures in hospitals (use of catheters, peritoneal 
dialysis, haemodialysis, parenteral nutrition, etc.). 
- The emergence of new and uncommon virulent fungal strains, especially 
favoured by an increase of the population mobility that facilitates a 
higher exposure to endemic fungal pathogens. 
 
 The evolution of fungal infections is further worsened by the fact that 
they are often difficult to diagnose, being recognized when they are already at 
an advanced stage. 
 Currently, there is a variety of antifungal drugs with different 
mechanisms of action. However, their effectiveness is limited due to a 
number of factors, such as fungistatic mode of action, lack of oral and 
intravenous preparations due to low solubility, drug toxicity and the 
development of drug resistance [6,7]. 
 From another standpoint, fungi cause significant losses in agronomy, 
taking in account that, depending on the crop type and the region, 
approximately 10-20% of the cultivated food plants are destroyed by plant 
pathogens, among them pathogenic fungi. The use of fungicides is still 
considered essential for increasing crop yields [8].  
 
1. Search for new antifungals 
 
 So, therefore, there is a clear need to search for new antifungal agents 
providing new mechanisms of action, with a broad spectrum of antifungal 
activity, fewer dose-limiting side effects, and economic [9,10].  
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 Nature offers a wide chemical diversity and natural products are an 
important source for the development of new therapeutic agents, in particular 
anti-infective agents. Some of the antifungal drugs most recently introduced 
in clinical practice (echinocandines and sordarines) are derived from natural 
products [4,11]. 
 Among the different natural sources of active principles, the plant 
kingdom has a special significance: 
 
- Plants offer a wide biodiversity that also involves a high chemodiversity.  
- It is estimated that less than 10% of the plant secondary metabolites have 
been isolated. In many cases these substances act as plant's defence 
mechanisms against attack by microorganisms, insects, etc. [12]. 
- Plants are an important source of medicinal preparations (extracts, teas, 
essential oils, etc.) used in traditional medicine since antiquity, and 
particularly many of them in the treatment of infectious diseases. It is 
estimated that 14-28% of species of higher plants are used in therapy. 
 
 In addition, to date, more than 600 herbal drugs showed antifungal 
activity, but only a small part of them have been studied concerning their 
active constituents. 
 Therefore, either as a source of pure compounds or extracts, the plant 
kingdom offers a huge potential for new drug development. 
 
2. Methods for research of antifungal agents from plants 
 
2.1. Selection of plant species 
 
 The first key point is the selection of plant species to be studied, from 
which the success of the research depends greatly. 
 The ethnopharmacological selection is based on existing knowledge 
about the traditional use of plants to treat diseases and it has shown to 
increase the probability of success in drug discovery, reducing empiricism.  
 The isolation and characterization of bioactive molecules from 
ethnopharmacologically selected plant species allows not only their use as 
drug or as chemical or pharmacological leads to produce new analogues, but 
also, and not less important, to set a scientific basis for the development and 
use of herbal drug preparations and to validate the use of traditional 
medicinal preparations. 
 Therefore, there is a strong interest in performing screenings of 
antifungal activity from medicinal plants used in traditional medicine for the 
treatment of fungal diseases [13-24].  
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 The first step in the ethnopharmacological-based research is the 
collection of data (most used plant species, part of the plant, forms of 
preparation and administration, uses, etc.) from indigenous population and 
their analysis. It is essential that the collected plant material is correctly 
authenticated by a botanist and that a voucher specimen is included in an 
internationally recognized herbarium. 
 Most of the research conducted by our group has been performed on 
Latin American plants. Latin America is a very suitable source of plant 
material for drug discovery because [14]: 
 
- It has a high biodiversity, one of the highest in the world in terms of 
vascular plants. 
- Many of the plant species have never been investigated for the research 
of bioactive agents. 
- There is a rich tradition in the use of medicinal plants and this 
ethnopharmacological knowledge has been relatively well preserved by 
the indigenous population. 
 
2.2. Preparation of crude extracts 
 
 Both, the appropriate extraction method and the most suitable solvents 
should be carefully selected. Concerning the method, usually plant extracts 
are obtained by maceration or percolation. Since the chemical nature of the 
active principles to be isolated is not known, the plant material is often 
subjected to a successive extraction with increasing polarity solvents (for 
example, Cl2CH2 and MeOH 95%) to obtain a wide range of compounds of 
different polarities. Additionally, an extract equivalent to the preparation 
commonly used in traditional medicine (usually aqueous or alcoholic extract) 
should be prepared. In the particular case of aromatic herbs, it is useful to 
obtain the essential oil by hydrodistillation. 
 
2.3. Screening of the antifungal activity 
 
 For the screening of antifungal activity and its monitoring during the 
isolation and purification of the active principles, test methods based on 
diffusion are mostly used, whereas to quantify the activity, both, dilution and 
diffusion methods may be employed. Reviews on the different techniques 
used for the evaluation of the antifungal activity of natural products can be 
found in Cos et al. [25], Das et al. [26], Engelmeier and Hadacek [8], Jacob 
and Walker [27] and Ríos et al. [28]. 
 One of the most widely employed methods to assess the antifungal 
activity of plant extracts is the agar disk diffusion assay [29].  
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 In our research, a number of plant extracts and essential oils, mainly 
coming from plants traditionally used for the treatment of skin diseases, were 
subjected to a screening of antifungal activity using the agar disk diffusion 
assay against a panel of fungal strains including both yeasts and filamentous 
fungi. Among them, there were opportunistic and skin and mucosal 
membranes pathogenic fungi, as well as phytopathogenic strains that can 
cause significant losses in agriculture and hinder food conservation [15,16]. 
The most active extracts were selected for subsequent bio-guided 
fractionation with the aim of isolating and characterizing the active 
principles. 
 
2.4. Bio-guided isolation and identification of active constituents 
 
 The most time-consuming step is the isolation and purification of the 
active compounds, which is mainly achieved through bio-guided fractionation.        
It is based on the combined use of preparative chromatographic techniques 
(e.g. column chromatography, medium- and high-pressure liquid 
chromatography, classical and centrifugal thin-layer chromatography, counter 
current chromatographic techniques) [30] together with bioautography with 
the aim of selecting in each step of the chromatographic fractionation the 
fractions containing the active compounds for further purification. 
 Contact bioautography allows the detection of active constituents in a 
complex mixture within a reasonable time. It is an agar diffusion method in 
which the components of a sample (raw extract or fraction) previously 
separated by thin-layer chromatography (TLC) diffuse from the stationary 
phase into the culture medium inoculated with the fungus that has been more 
sensitive to the crude extract in the antifungigram [31]. 
 To do this, the already developed and dried TLC plate is placed overlaid 
on the inoculated Sabouraud dextrose agar medium, leaving enough time            
(1 h at 4ºC) so that diffusion takes place. Then, the TLC plate is removed and 
the inoculated agar incubated at 30ºC for 48 h. The growth inhibition zones 
observed are related to the substances separated on a TLC reference plate 
developed with the same mobile phase. In this way, active compounds can be 
detected on the TLC plate and the fractionation can be directed to the 
isolation of these compounds. 
 Some considerations should be taken into account when evaluating the 
results of a bioautography: a) due to the limited exposure time (usually 1 h) 
of the inoculum to the potential antifungal agents the sensitivity is lower than 
in the antifungigram, b) according to their polarity the components of the 
sample will diffuse differently through the agar, and c) the result may be 
affected by the stability of the product on the TLC plate [27]. 
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 Nonetheless, bioautography is a useful technique which complements the 
antifungigram, since it allows the detection of active substances that in the 
initial raw extract are present in a very low concentration, or that coexist with 
others that antagonize their activity. 
 Furthermore, it is necessary to bear in mind that during the fractionation 
of an active extract a loss of activity may occur due to a degradation of active 
principles during isolation, or to the separation of different components of the 
extract acting synergistically. 
 Finally, once the active compounds are purified, their chemical structure 
should be established by using different standard spectroscopic techniques, 
such as UV-Vis, IR, different types of mass spectrometry, and a variety                
of experiments of 1H-NMR and 13C-NMR, involving both mono- and 
bidimensional methods. 
 Particularly, in the case of essential oils, identification of the constituents 
of the oil and their fractions is usually achieved by means of qualitative              
and quantitative analysis by GC-FID, GC-MS [32] and also, if necessary, by              
13C-NMR [33-35]. 
  
2.5. Evaluation of the antifungal activity 
 
 The antifungal activity of the extracts, essential oils and pure isolated 
compounds should be quantitatively evaluated through determination of their 
minimal inhibitory concentration (MIC) and minimal fungicidal concentration 
(MFC). 
 The MIC is defined as the minimal concentration of a product that 
inhibits the visible growth of microorganisms. It allows quantification of the 
sensitivity of a certain fungal strain to an antifungal agent. MIC is usually 
determined using either broth macrodilution or microdilution methods, the 
latter being the most used, through a standard two-fold dilution technique 
[36]. In the case of lipophilic substances that are dissolved in solvents poorly 
soluble in water, addition of Tween 80 as an emulsifier is recommended. 
 Because samples may not be 100% antifungal at their MIC, viable fungal 
cells may remain in the wells in which fungal growth is not appreciated by 
sight. Thus, the determination of the MFC is also necessary to establish their 
fungicidal activity. The MFC can be established technically by extending the 
MIC (microdilution method) [37]. 
 
3. Major chemical groups with antifungal activity 
 
 A number of compounds isolated from plants are reported to have 
antifungal activities. However, development of useful antifungal drugs from 
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the majority of them has not yet been possible, even though mainstream 
medicine is increasingly receptive to the use of antimicrobial and other drugs 
derived from plants, because of the resistances developed against traditional 
antibiotics [12]. 
 One of the reasons is the fact that most of the antifungal plant products, 
i.e. extracts, essential oils or pure constituents, have only been tested for their 
in vitro activities, their effectiveness in animals and/or humans remaining 
unknown. Pharmacokinetics, undesirable effects, interactions and toxicity 
should also be studied [38]. 
 The interest of finding new antifungal compounds from plants is that 
they can constitute precursors leading to more active antifungal drugs [12].  
In addition, potential benefits of combination therapy which include 
enhanced potency of antifungal efficacy, reduced selection of resistant 
organisms (particularly for flucytosine), and reduced toxicities due to lower 
dosing, are important to be taken into account. 
 Several chemical groups of plant constituents have been reported for 
their antifungal activity. Among them: some fatty acids, peptides and 
alkaloids, but it should be especially highlighted the groups of polyphenols 
and terpenoids which have furnished a huge variety of active structures. 
Interesting reviews have been published [9,12,38-40]. 
 Examples of active compounds with different chemical structures, some 
of them the result of research conducted by our group, are discussed below. 
 
3.1. Antifungal fatty acids 
 
 Some fatty acids have shown antifungal activity mainly due to their 
capacity to disrupt the bacterial membrane. They are able to interfere in the 
cell membrane structure displacing phospholipids and increasing its 
permeability. A well-known example is undecylenic acid, a semisynthetic 
product prepared from ricinoleic acid obtained from castor oil, the oil from 
seeds of Ricinus communis. Undecylenic acid is mainly used in the treatment 
of superficial mycoses. 
 During the search for new antifungals from Paraguaian plants, a series of 
fatty acids were isolated by our group from the bark of Calycophyllum 
spruceanum var. multiflorum (Griseb.) Chodat & Hassl. (Rubiaceae). Bio-
guided fractionation of the dichloromethane extract afforded a mixture of 
eight fatty acids which were identified through GC-MS, HPLC-MS, 1H- and 
13C-NMR analysis. Five of them were acetylenic: 6-hexadecinoic acid,                
6-heptadecinoic acid, 6-octadecinoic acid, 6-nonadecinoic acid and                
6-eicosinoic acid, whereas the other three were saturated: palmitic acid, 
heptadecanoic acid and stearic acid. Acetylenic fatty acids are very rarely 
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found in nature, and particularly three of them constituted new natural 
products: 6-heptadecinoic, 6-nonadecinoic and 6-eicosinoic acids. The mixture 
was active against the dermatophytes Microsporum gypseum and Tricophyton 
mentagrophytes with MIC and MFC values of 0.25 μg/mL, lower than those of 
the reference drugs nystatin (MIC and MFC values from 1.25 to 2.50 μg/mL) 
and amphotericin B (MIC and MFC values from 0.31 to 0.63 μg/mL) [41]. 
 
3.2. Polyphenols 
 
 Many polyphenols, including simple phenols, flavonoids, coumarins, 
tannins and quinone derivatives, have been reported to have antifungal 
activity, which is partly dependent on the number and position of hydroxyl 
groups. They may act by inhibiting microorganism enzymes, possibly 
through reaction with sulfhydryl groups or through less specific interactions 
with proteins [12]. 
 The antifungal spectra, potency and fungicidal properties of two 
chalcones from Zuccagnia punctata Cav. (Fabaceae), a plant used in 
traditional medicine in Argentina as antiseptic and wound-healing            
poultices, evidenced that they could have potential as antifungal agents for             
human beings. Particularly, 2’,4’-dihydroxy-3’-methoxychalcone and 2’,4’-
dihydroxychalcone (Fig. 1) evidenced very strong activities against several 
clinical strains of the dermatophytes T. mentagrophytes and T. rubrum with 
MIC values in the range of 1.9-15.6 µg/mL and MFC values between 1.9 and 
7.8 µg/mL. In addition, 2’,4’-dihydroxychalcone showed a moderate activity 
against clinical isolates of the yeasts Candida sp. and Cryptococcus neoformans. 
Regarding their mode of action, both chalcones appeared to be fungicidal 
rather than fungistatic; moreover, 2’,4’-dihydroxychalcone did not disrupt the 
fungal membranes up to 4×MFC and did not act by inhibiting the synthesis of 
polymers of the fungal cell wall. So, their mechanism would be different than 
that of most antifungal drugs in clinical use, i.e. amphotericin B, azoles or 
echinocandins [42]. 
 In the course of our search for new antifungals from Latin-American 
plants different active polyphenolic structures were identified in our 
laboratory, among which flavonoids, caffeic acid derivatives and lignans. 
 Two isoflavones, genistein and biochanin A, were isolated from the bark 
of Andira surinamensis (Boudt.) Splitz (Leguminosae) collected in Perú. It is 
a high tree mainly distributed in tropical America, whose bark is used in 
traditional medicine for different purposes. The dichloromethane extract, 
which showed a good activity against several fungal strains in the agar disk 
diffusion assay [15], was subjected to activity-guided fractionation yielding 
the two isoflavones. Particularly, biochanin A (Fig. 1) evidenced antifungal 
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activity especially against yeasts and dermatophytes. Both isoflavones have 
previously been isolated from other Andira sp. [43] and are known to have 
antifungal activity [44]. In addition, the activity of the methanol extract 
against the dermatophyte M. gypseum and T. mentagrophytes was mainly 
related to the presence of condensed tannins [45]. 
 
 
R= -H 2’,4’-dihydroxychalcone
R= -OCH3 2’,4’-dihydroxy-3’-
methoxychalcone 
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Figure 1. Some antifungal polyphenols isolated from Latin-American plants 
[41,42,45]. 
 
 The isolation and identification of a new antifungal caffeic acid 
derivative was performed from the methanol extract of the aerial parts of 
Geophila repens (L.) I. M. Johnston from Paraguay, a Rubiaceae used by the 
Quechuas for the treatment of fungal infections [46]. In this case, the active 
methanol extract was subjected to partition with increasing polarity solvents, 
namely dichloromethane, ethyl acetate and butanol, the fraction obtained with 
the last solvent being the most active against C. neoformans, M. gypseum and 
T. mentagrophytes, its activity even persisting for one week in the agar disk 
diffusion assay. Fractionation by successive column chromatography on 
Sephadex® LH-20 led to the isolation of an ester of caffeic acid and malic 
anhydride identified as 2,5-dioxotetrahydrofuran-3-yl caffeate (malic 
anhydride caffeate) (Fig. 1), a compound not previously described, as the 
main responsible for the activity [47]. 
 Piper fulvescens C. DC. is an herbaceous plant growing in Paraguay 
whose leaves are used in traditional medicine [48]. Activity-guided 
fractionation of their dichloromethane extract, which showed growth 
inhibitory activity against the yeasts Candida albicans and Saccharomyces 
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cerevisiae, as well as against the dermatophytes M. gypseum and                        
T. mentagrophytes [15], led to the isolation of three neolignans identified as 
conocarpan, eupomatenoid 5 and eupomatenoid 6 (Fig. 2), for which 
antifungal activity had not previously been described. Conocarpan showed 
the broadest spectrum of activity, being active against yeasts and 
dermatophytes, whereas eupomatenoid 6 showed the strongest activity 
against M. gypseum and T. menthagrophytes with MIC values of 0.5 and              
1.0 µg/mL, respectively. Moreover, eupomatenoid 5 turned out to be the least 
active. These results suggest that the absence of a methoxy group at 3’ 
position of the phenyl-propenyl-benzofuran structure plays an important role 
in the antifungal activity, whereas the saturation of the C2-C3 bond 
influences the selectivity [49]. 
 
 
R= -CH3   Eupomatenoid 5 
R= -H   Eupomatenoid 6 
 
Conocarpane 
 
Figure 2. Antifungal neolignans from the leaves of Piper fulvescens [49]. 
 
3.3. Terpenoids 
 
 Among terpenes a variety of chemical structures showing interesting 
antifungal activities have been reported in recent years [9]. Their mechanism 
of action is not fully understood although it has been suggested to involve 
membrane disruption due to their lipophilic nature [12]. 
 A high-throughput whole animal assay for the identification of antifungal 
compounds which uses the nematode Caenorhabditis elegans as a 
heterologous host [50] was performed to screen the activity of 2560 natural 
products against C. albicans. From all of them, those compounds that 
produced higher survival rates of the infected nematodes were 
polyglycosylated saponins with different types of skeletons. Two of them, a 
spirostanic one (aginoside) and a triterpenic one derived from barrigenol, 
were selected for further studies concerning their mechanisms of action. They 
inhibited C. albicans isolates at relatively low concentrations (16 and                     
32 µg/mL), including isolates resistant to clinically used antifungal agents, 
such as fluconazole and echinochandins. C. albicans hyphae and biofilm 
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formation were also disrupted by these two saponins at concentrations below 
the MIC. Furthermore, no hemolysis of erythrocytes was observed at three-
fold the MIC for C. albicans, suggesting the saponins may have a preference 
for binding to fungal ergosterol when compared to cholesterol of the 
erythrocyte membranes [51]. 
 One of the few antifungal products from plants that have been subjected 
to clinical trials is the methanol extract from leaves of Solanum 
chrysothrichum Schldh. (Solanaceae), a herbal drug used in Mexico for the 
treatment of fungi-associated dermal and mucosal infections, particularly 
recommended to cure Tinea pedis. In vitro assays showed antifungal activity 
against T. mentagrophytes, T. rubrum and M. gypseum, and a preliminar 
clinical study performed with the methanolic extract at 5% in a cream applied 
topically on patients affected of Tinea pedis showed clinical success with no 
side effects [52]. Later on, five new antimycotic spirostanic saponins were 
isolated and identified [53,54]. Clinical trials with a standardised methanol 
extract demonstrated not only the therapeutic efficacy and tolerability when 
applied topically as a cream against T. pedis [55] but also on Pityriasis capitis 
[56] and as suppository on Candida sp.-associated vaginal infection [57].  
 The screening on plant products with antifungal activity based on                
an ethnopharmacological approach, carried out by our research group, 
allowed the characterization of several antimycotic terpene compounds,                
for which antifungal activity had not previously been reported. Among              
them, the diterpene lactone acanthoaustralide and the sesquiterpene ester               
6-cinnamoyloxy-1-hydroxyeudesm-4-en-3-one (Fig. 3) were respectively 
isolated through bio-guided fractionation from the dichloromethane extracts 
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O
O
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6-Cinnamoyloxy-1-hydroxy- 
eudesm-4-en-3-one 
O
OH
O
OH
 
Acanthoaustralide 
 
Figure 3. The sesquiterpene ester 6-cinnamoyloxy-1-hydroxy-eudesm-4-en-3-one and 
the diterpene lactone acanthoaustralide are the antifungal principles of the roots of 
Vernonanthura tweedieana and the leaves of Acanthospermum australe, respectively 
[58,59]. 
Roser Vila et al.  34 
from leaves of Acanthospermum australe (Loefl.) O. Kuntze and from roots 
of Vernonanthura tweedieana (Baker) H. Rob. (=Vernonia tweedieana 
Baker), two Asteraceae traditionally used in Paraguay for the treatment of 
skin diseases such as eczema and itching. Both compounds evidenced a 
strong activity against T. mentagrophytes with the same MIC and MFC 
values: 2 μg/mL in the case of acanthoaustralide and 4 μg/mL in the case of 
the sesquiterpene derivative [58,59].  
 
3.4. Essential oils 
 
 Special consideration should be deserved to essential oils, many of which 
have been used for centuries for their antiseptic activity. Antimicrobial essential 
oils are nowadays used in the treatment of dermal and mucosal infections, such as 
acne, onychomycosis, vaginal infections, gingivitis or teeth and gums healthcare, 
as well as food preservatives and in the control of crop diseases. 
 A number of papers dealing with the antifungal activity of many essential 
oils have been published during the last decades, some of them discussing 
relationships between structures and activities and with interesting 
contributions on their mechanism of action, which is complex and has not yet 
been fully explained [39,40,60-66]. 
 Different types of constituents of the essential oils have proven 
antimycotic properties (Fig. 4). Those that have reported the strongest activity are 
phenolic monoterpenes (e.g. thymol and carvacrol), phenylpropanoids (such                     
as eugenol), alcoholic monocyclic monoterpenes (e.g. α-terpineol and terpinen- 
4-ol), and bicyclic monoterpene hydrocarbons (e.g. α-pinene) and ketones                
 
 
Thymol 
 
 
Carvacrol 
 
 
Terpinen-4-ol
 
 
α-Terpineol 
 
 
Eugenol 
 
 
α-Pinene 
 
 
Camphor 
  
Figure 4. Typical antifungal compounds found in essential oils. 
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(e.g. camphor). The acidic nature of the hydroxyl group of phenols facilitates 
a hydrogen bond with enzyme active centres, being responsible of their high 
activity [67,68]. 
 In the course of our research, several essential oils have demonstrated 
strong antifungal activities. The investigation of their composition together 
with bio-guided fractionation led to the identification of the main active 
constituents responsible for the activity.  
 From the antifungal essential oils from Piper amalago L. collected in 
Panama, a series of four new 2-acyl-3-hydroxycyclohex-2-en-1-ones, which 
represented more than 50% and 85% of the oils of the leaves and the stems, 
respectively, were isolated and their structures were established by EI-MS 
and NMR spectroscopy  as 2-hexanoyl- (1), 2-octanoyl- (2), 2-decanoyl- (3) 
and 2-dodecanoyl-3-hydroxycyclohex-2-en-1-one (4) (Fig. 5). 1 and 2, the 
two main constituents of the essential oils, showed a good antifungal activity 
against different yeasts. The hexanoyl- compound (1) showed the highest 
activity against C. albicans and S. cerevisiae, whereas the octanoyl- 
derivative (2) was the most active against Candida lactis-condensi and the 
decanoyl- one (3) only showed activity against C. lactis-condensi. These 
findings suggested that the length of the lateral chain modulates the activity 
[69,70]. 
 The essential oil from fresh leaves of Plinia cerrocampanensis Barrie 
(Myrtaceae) from Panama, mainly constituted by oxygenated sesquiterpenes 
(65.9%), especially α-bisabolol (42.8%), bisabolol oxide B (10.3%) and 
trans-nerolidol (9.4%), was assayed against several fungal strains showing 
the strongest activity against M. gypseum, T. mentagrophytes and T. rubrum 
with MIC values from 32 to 125 μg/mL [71]. 
 The unusual compound (-)-5,6-dehydrocamphor was found to be the 
major constituent in the essential oil from aerial parts of Zuccagnia punctata 
Cav. (Fabaceae) from Argentina, reaching percentages from 12.3% to 56.5%. 
 
(CH2)n
O
O
OH  
1: n=1 2-hexanoyl-3-hydroxycyclohex-2-en-1-one 
2: n=3 2-octanoyl-3-hydroxycyclohex-2-en-1-one 
3: n=5 2-decanoyl-3-hydroxycyclohex-2-en-1-one 
4: n=7 2-dodecanoyl-3-hydroxycyclohex-2-en-1-one 
 
Figure 5. Antifungal acyl-hydroxycyclohexenones of the essential oils from                 
Piper amalago [69]. 
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It was isolated from nature for the first time and its structure was completely 
elucidated from NMR data. The essential oil showed antifungal activity 
against the dermatophytes M. gypseum, T. rubrum and T. mentagrophytes 
with MIC values between 15.6-125 μg/mL, T. rubrum being the most 
susceptible species [72]. 
 The composition and the antifungal activity of the essential oil from the 
rhizome and root of Ferula hermonis Boiss. (Apiaceae), a perennial shrub 
that grows on the Hermon mountain between Lebanon and Syria, evidenced 
this species as a potential source of interesting antifungal agents. The 
exhaustive analysis of the essential oil combined with successive bio-guided 
fractionations afforded different active products among which the unusual 
acetylenic compound 3,5-nonadiyne (Fig. 6), α-bisabolol and a fraction with 
73% jaeschkeanadiol benzoate were the most active against the 
dermathophytes M. gypseum and T. mentagrophytes. Particularly, the fraction 
with the latter compound showed the strongest activity with MIC and MFC 
values superior or equivalent to those of the positive controls amphotericin B 
and nystatin [32].  
 The daucane aryl esters jaeschkeanadiol benzoate (teferidin) and 
jaeschkeanadiol p-hydroxybenzoate (ferutinin) (Fig. 6) were also isolated 
from hexane and dichloromethane extracts of the rhizome and root of Ferula 
hermonis. Determination of MIC and MFC values of both compounds 
evidenced a stronger antifungal activity for ferutinin than for teferidin. 
Particularly, T. mentagrophytes was the most sensitive strain with MIC and 
MFC values ranging from 8 to 256 μg/mL [73]. These results suggest that the 
presence of a phenolic hydroxyl in the acidic moiety of the ester, in the case 
     
 
3,5-Nonadiyne 
   
R= -H Teferidin 
 (jaeschkeanadiol benzoate) 
 
R= -OH Ferutinin 
 (jaeschkeanadiol p-hydroxybenzoate)
 
Figure 6. Antifungal constituents from the rhizome and root of Ferula hermonis 
[32,73]. 
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of jaeschkeanadiol p-hydroxybenzoate, enhances the antifungal activity. This 
would be consistent with the fact that compounds with phenolic structures, 
like carvacrol, eugenol and thymol show stronger antimicrobial activities 
than those lacking a phenol group, as for example p-cymene [39,40,74]. 
 Essential oils may induce visible signs of their action against fungi that 
can be observed as morphological changes both under microscope and as 
colony macro-features. Thus, eugenol and carvacrol have been found to cause 
significant deformations of the hyphae in food spoiling mould Cladosporium 
herbarum, which were related to their action on some cell wall enzymes, 
such as chitinases and glucanases [75]. Borneol induces morphological 
changes in cell walls and cellular organelles of Aspergillus fumigatus and 
Epidermophyton floccosum and inhibits mycelial growth of both filamentous 
fungi [76]. Furthermore, the essential oil from Thymus vulgaris inhibited 
mycelial development and germination of sporangiospores in Rhizopus 
oryzae [77], whereas the oil from Zataria multiflora caused vacuolisation of 
the cytoplasm and cell swelling, detachment of the cell membrane from the 
cell wall and deformation of mycelia in Aspergillus flavus [78]. Souza et al. 
[79] reported on the efficacy of Origanum essential oils against potentially 
pathogenic fungi, finding that the oil from O. vulgare completely inhibited 
radial mycelia growth of T. rubrum and M. canis and elicited disruption of 
cell structure in Aspergillus flavus. 
 Some studies evidenced that morphological modifications in the fungal 
cell may be induced even at sub-MIC concentrations [38]. In this way, 
Zuzarte et al. [62,65] found that essential oils from Portuguese Lavandula sp. 
completely inhibited filamentation in Candida albicans at concentrations as 
low as MIC/16. Also, farnesol derivatives prevent the conversion of yeast 
form into the invasive filamentous growth form of C. albicans at sub-
inhibitory levels [80]. These findings could be of potential interest for the 
treatment of candidiasis.  
 Concerning their mechanism of action, as complex mixtures of a variety 
of chemical structures, essential oils do not seem to act on specific targets in 
fungal cells but to trigger different types of radical reactions [38,67,81].  
 Degradation of the cell wall and damage to both cytoplasmic and 
mitochondrial membranes have been proposed as the main mechanisms 
leading to changes in permeability and subsequent leakage and cell death 
[81]. It has been reported that lipophilic compounds accumulate in the lipid 
bilayers of the cell membrane altering its permeability and causing disruption 
of lipid packing and leakage of inorganic ions, while more hydrophilic 
constituents can enter the cytoplasm [38]. A mechanism of action related to 
damage of mitochondrial membranes and subsequent metabolic arrest rather 
than to direct disruption of cytoplasmic membrane or cell wall has been 
suggested by Zuzarte [65]. 
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 In the last years, investigations on the mechanisms of action of essential 
oils and their constituents showed that the antifungal activity is mediated 
through several mechanisms other than membrane disruption and inhibition 
of cell division. Inhibition of both ergosterol biosynthesis and H+-ATPase 
leading to disruption of ion homeostasis and cell death [82-86] and induction 
of oxidative stress [87] have been proposed as main targets of antifungal 
essential oils. Several terpenoids inhibit microbial oxygen uptake and 
oxidative phosphorylation, the phenolic and non-phenolic alcohols exhibiting 
the strongest inhibitory effects, followed by aldehydes and ketones [66]. 
 Synergistic effect between the essential oil constituents or between 
different essential oil mixtures against yeasts and dermatophytes have been 
reported by several authors [60,88,89]. But, due to increasing fungal 
resistance to classical antifungal drugs and their toxicity, what is more 
interesting from a clinical point of view is that combinations of essential oils 
or their pure constituents with commercial antifungal drugs used in 
therapeutics, such as amphotericin B or ketoconazole, can potentiate the 
activity of the latter and, thus, may lead to a dose reduction and minimization of 
secondary effects [90-94]. Although the combination of essential oils with other 
drugs can be very useful it has to be carefully considered, since depending on the 
percentage of each one antagonistic effects may also occur [40]. 
 
4. Conclusions 
 
 Despite the enormous progress made in recent decades in medicine, fungal 
infections are still an unsolved health problem, mainly due to the fact that the 
available antifungal drugs are of limited effectiveness. The plant kingdom is a 
source of medicinal preparations used in Traditional Medicine that offers a 
wide chemical diversity, making it of huge potential for new drug development. 
The research developed over the last years by different groups has led to the 
characterization of a variety of chemical structures with outstanding antifungal 
activity. Unsaturated fatty acids, polyphenols, triterpene derivatives and, 
particularly, essential oils have been shown as promising groups, some of them 
showing a synergistic effect with commercial antifungal drugs used in 
therapeutics. In case of complex mixtures such as essential oils synergy within 
some of their constituents have also been reported. 
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